Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FP7AW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,835
Award facts
- Contract value 100% obligated
- $14,834.79 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $14,834.79 by the Defense Logistics Agency (DLA) for the supply of Entyvio 300 mg vials. The contract, awarded on September 25, 2025, carries an ultimate completion date of October 17, 2025, and was issued without a set-aside designation. This delivery order falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499,999,999 single-award vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting medical supply needs across military health facilities.
Entyvio (vedolizumab) is a biologic medication indicated for the treatment of inflammatory bowel diseases, and its procurement through this delivery order reflects the DLA's responsibility for maintaining pharmaceutical inventories across Department of Defense healthcare facilities. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing delivery orders for branded and generic medications, biologics, vaccines, and specialty pharmaceuticals. The company's federal contracting experience and status as a woman-owned small business have enabled it to compete effectively in federal procurement markets while supporting the Department of Defense's healthcare operations nationwide.
Quick answers
Who was awarded contract SPE2DB25FP7AW?
SPE2DB25FP7AW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 25, 2025.
How much is contract SPE2DB25FP7AW worth?
The government has obligated $14,835 on SPE2DB25FP7AW.
Is contract SPE2DB25FP7AW an order under another contract?
Yes. SPE2DB25FP7AW is a delivery order under SPE2DB22D9311, an indefinite delivery contract.
Was contract SPE2DB25FP7AW competed?
The extent of competition for SPE2DB25FP7AW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award